US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VERIDIEN CLIMATE ACTION ETF

18.61

0.0000

Volume:- -

Turnover:- -

Market Cap:4.09M

PE:- -

High:18.61

Open:18.61

Low:18.61

Close:18.61

52wk High:21.28

52wk Low:16.48

Shares:220.00K

Float Shares:220.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Lumos Diagnostics Boosts FebriDx Sales as It Advances U.S. CLIA Waiver and Secures Full Medicare Reimbursement

Press Release: Natera to Report its Third Quarter Results on November 6, 2025

Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.

Press Release: Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CLIA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLIA\",,,,,undefined,":{"symbol":"CLIA","market":"US","secType":"STK","nameCN":"VERIDIEN CLIMATE ACTION ETF","latestPrice":18.61,"timestamp":1739998800000,"preClose":18.61,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":220000,"shares":220000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"02-19 16:00:00 EST","open":18.61,"high":18.61,"low":18.61,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":18.61,"sharesOutstanding":220000,"nav":18.69,"aum":4111800,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLIA\",,,,,undefined,":{"symbol":"CLIA","floatShares":220000,"roa":"--","roe":"--","lyrEps":0,"shares":220000,"dividePrice":0,"high":18.61,"amplitude":0,"preClose":18.61,"low":18.61,"week52Low":16.48,"pbRate":"--","week52High":21.28,"institutionHeld":0,"latestPrice":18.61,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":18.61,"prevYearClose":20.7542},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLIA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-19","symbol":"CLIA","reason":null,"defaultRemindTime":1724074200000,"announcedDate":"2024-08-05","type":"delisting","dateTimestamp":1724040000000},{"date":"2023-12-26","symbol":"CLIA","amount":0.080227,"announcedDate":"2023-12-22","type":"dividend","market":"US","newRecordDate":"2023-12-27","defaultRemindTime":1703601000000,"name":"VERIDIEN CLIMATE ACTION ETF","recordDate":"2023-12-28","payableDate":"2023-12-27","currency":"USD","dateTimestamp":1703566800000,"payDate":"2023-12-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLIA\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-26","recordDate":"2023-12-27","paymentDate":"2023-12-28","value":0.080227,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLIA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607772803","title":"Lumos Diagnostics Boosts FebriDx Sales as It Advances U.S. CLIA Waiver and Secures Full Medicare Reimbursement","url":"https://stock-news.laohu8.com/highlight/detail?id=2607772803","media":"TIPRANKS","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607772803?lang=en_us&edition=fundamental","pubTime":"2026-01-29 13:18","pubTimestamp":1769663902,"startTime":"0","endTime":"0","summary":"Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) just unveiled an announcement. Lumos Diagnostics reported unaudited revenue of US$2.7 million for the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lumos-diagnostics-boosts-febridx-sales-as-it-advances-u-s-clia-waiver-and-secures-full-medicare-reimbursement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lumos-diagnostics-boosts-febridx-sales-as-it-advances-u-s-clia-waiver-and-secures-full-medicare-reimbursement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLIA"],"gpt_icon":0},{"id":"2579117004","title":"Press Release: Natera to Report its Third Quarter Results on November 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579117004","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579117004?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:06","pubTimestamp":1761822360,"startTime":"0","endTime":"0","summary":"Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments  in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.CONTACT:    Investor Relations: Mike Brophy, CFO, Na","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4604","LU1064131342.USD","TM","03160","LU0345770308.USD","BK4585","LU0012050646.USD","LU0053671581.USD","BK4588","LU2065170008.USD","NTRA","LU2065169927.USD","LU2324357040.USD","CLIA","LU2065171311.SGD","LU2065731478.USD","LU0345770993.USD","LU1988902786.USD","BK4139","LU2065171402.SGD","LU2264538146.SGD","BK4555","LU0963586101.USD","LU0106261612.USD"],"gpt_icon":0},{"id":"2575468127","title":"Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2575468127","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575468127?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:19","pubTimestamp":1760617140,"startTime":"0","endTime":"0","summary":"- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167894/0/en/Henry-Schein-and-Biomerica-Enter-into-Marketing-Services-Agreement-for-Biomerica-s-inFoods-IBS-Test-in-the-U-S.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4585","HSIC","BK4175","BK4588","CLIA","BMRA"],"gpt_icon":0},{"id":"2573292351","title":"Press Release: Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2573292351","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573292351?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:19","pubTimestamp":1759925940,"startTime":"0","endTime":"0","summary":"-- Brings decades of leadership in laboratory testing, clinical diagnostics,-- Extensive track record in commercializing advanced laboratory testing and. \"Gary's exceptional track record of building successful diagnostics businesses, forging strategic partnerships, and delivering shareholder value will be invaluable as Biomerica continues to advance its innovative diagnostic portfolio,\" said Zack Irani-Cohen, Chief Executive Officer of Biomerica. \"We are excited to welcome him to our Board and look forward to his insights as we expand our market presence and pursue our mission of improving patient care and access to our innovative products.\". \"I am honored to join Biomerica's Board of Directors at such an exciting time in the company's growth,\" said Mr. Huff. \"Biomerica's innovative pipeline, particularly the inFoods IBS product, has the potential to transform how patients and physicians manage the widespread condition of irritable bowel syndrome. I look forward to contributing to the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","BK4082","BMRA","CLIA","BK4232"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CLIA\",params:#limit:6,delay:false,,,undefined,":[]}}